Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension

Study:

An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension

Rationale:

n/a

Purpose:

This study provides UT-15C (treprostinil diethanolamine) to eligible patients with pulmonary arterial hypertension who have completed the TDE-PH-301, TDE-PH-302 or TDE-PH-308 studies. The purpose of this study is to assess the long term safety of UT-15C and to assess the effects of continued treatment with UT-15C on exercise capacity after one year of treatment.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Pulmonary Arterial Hypertension Drug: Treprostinil diethanolamine Phase 3

Verified by United Therapeutics February, 2013

Sponsored by: United Therapeutics
Information provided by: United Therapeutics
ClinicalTrials.gov identifier: NCT01027949

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Kevin Laliberte, PharmD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site